SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

2 days ago · Learn more about the SKYRIZI® On-Body Injector (OBI). See Important Safety Information and Prescribing Information.

SKYRIZI (risankizumab-rzaa) is available in a 600 mg/10 mL vial for intravenous infusion and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

• The On-Body Injector and the prefilled cartridge are not made with natural rubber latex. • Keep SKYRIZI and all medicines out of the reach of children. Storage and preparation for use • Keep SKYRIZI in the original carton to protect from light and physical damage until time to use.

SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Dosage Forms and Strengths: SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL single-dose vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Skyrizi comes in a prefilled cartridge that must be placed into a special device called an on-body injector. This device is intended to be used only one time. This means that a new on-body...

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Jul 8, 2024 · Skyrizi (risankizumab-rzaa) comes in three different forms you or a caregiver can administer at home: a prefilled syringe, an injection pen, and an on-body injector. They’re all prefilled with one dose you can inject into your stomach or thigh.

Jul 10, 2023 · It’s worth noting that Skyrizi is the first treatment for Crohn’s that targets the interleukin-23 (IL-23) protein, which is responsible for inflammation in our bodies. By going after IL-23, Skyrizi helps reduce inflammation that can contribute to Crohn’s symptoms.